U.S. Markets close in 46 mins

NovaBay Pharmaceuticals Q4 Earnings Outlook

Benzinga Newsdesk

On Tuesday, NovaBay Pharmaceuticals (NYSE: NBY) will release its latest earnings report. Decipher the announcement with Benzinga's help.

Earnings and Revenue

NovaBay Pharmaceuticals EPS will likely be near a loss of 4 cents while revenue will be around $5.97 million, according to analysts.

In the same quarter last year, NovaBay Pharmaceuticals posted a loss of 13 cents per share on sales of $4 million. If the company were to report inline earnings when it publishes results Tuesday, earnings would be up 69.23 percent. Revenue would be up 46.43 percent on a year-over-year basis.

View more earnings on NBY

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

 

Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.08 -0.12 -0.1 -0.07
EPS Actual -0.16 -0.11 -0.26 -0.13

 

Stock Performance

Over the last 52-week period, shares are down 7.89 percent. Given that these returns are generally negative, long-term shareholders are probably down going into this earnings release.

Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The average rating by analysts on NovaBay Pharmaceuticals stock is a Buy. The validity of this rating has maintained conviction over the past 90 days.

Conference Call

Don't be surprised to see the stock move on comments made during its conference call. NovaBay's Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.

See more from Benzinga

© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.